维拉帕米在控制半乳糖性白内障中的作用

来源 :眼科研究 | 被引量 : 0次 | 上传用户:sdtt1314
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的 观察维拉帕米 (verapamil)在半乳糖性白内障形成和发展过程中的作用。方法  5 5只Wistar雄性大鼠分为 4组 ,2组动物每日腹腔注射 5 0 %D 半乳糖两次 ,剂量为 30ml/ (kg·d) ,其中 1组每天皮下注射维拉帕米 12mg/ (kg·d) ,共 30天。另 2组注射相同剂量的生理盐水 ,其中 1组动物也给予皮下注射维拉帕米 ,观察时间相同。术后不同时间散瞳观察晶状体的动态变化 ,用日本岛津AA 6 40 13型原子吸收分光光度计检测血清和晶状体内的Na+ ,K+ ,Ca2 + 浓度。结果 半乳糖注射 30天后 ,未经治疗组几乎所有动物形成核性或核性以上的白内障 ,而治疗组所有动物晶状体均未形成核性混浊。维拉帕米能明显减轻白内障晶状体中Ca2 + ,K+ ,Na+ 浓度和Na+ /K+ 的变化。结论 维拉帕米能有效阻止半乳糖性白内障的形成和发展。 Objective To investigate the role of verapamil in the formation and development of galactose cataract. Methods Fifty five Wistar male rats were divided into four groups. Two groups of animals were injected intraperitoneally with 50% D galactose twice a day at a dose of 30 ml / (kg · d). One group was subcutaneously injected with verapamil 12 mg / (kg · d) for a total of 30 days. The other two groups were injected with the same dose of saline, of which 1 group of animals were also given subcutaneous injection of verapamil, the same observation time. Dyspnea was observed at different times after surgery to observe the dynamic changes of lens. The concentrations of Na +, K + and Ca2 + in serum and lens were measured by Shimadzu AA 6 40 13 atomic absorption spectrophotometer. Results After 30 days of galactose injection, almost all the animals in the untreated group formed cataracts with nuclear or above nuclearity, and no lens opacification was found in all animals in the treatment group. Verapamil can significantly reduce the changes of Ca2 +, K +, Na + and Na + / K + in cataractous lens. Conclusion Verapamil can effectively prevent the formation and development of galactose cataract.
其他文献
目的 :观察连续延长眼内有效气泡填塞时间治疗复杂的玻璃体视网膜病变的疗效。方法 :对 5 6眼玻璃体切割术后 ,认为需硅油充填者 ,采用经眼前节行眼内连续气液交换术 ,按眼内